Myszkowski Kenneth Allen's Form 4 filing
Arrowhead Pharmaceuticals, Inc. (ARWR) · filed Jan 8, 2024
- Accession no.
- 0001628280-24-000866
- Filed
- Jan 8, 2024
- Trade date
- Jan 4-5, 2024
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Checked
This filing lists 4 non-derivative transactions and 0 derivative transactions. Open-market sales total $567.9K. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Myszkowski Kenneth AllenCIK 0001486672 | Officer (Chief Financial Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jan 4, 2024 | Common Stock | AGrant or awardAcquired | +75,000 | $0.00 | $0 | 456,704 | Direct | |
| Jan 5, 2024 | Common Stock | SSaleDisposed | −1,400 | $34.04 | −$47,656 | 455,304 | Direct | |
| Jan 5, 2024 | Common Stock | SSaleDisposed | −5,800 | $34.97 | −$202,826 | 449,504 | Direct | |
| Jan 5, 2024 | Common Stock | SSaleDisposed | −8,904 | $35.65 | −$317,427.6 | 440,600 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.